TY - JOUR
T1 - Prognostic effect of body mass index in patients with advanced NSCLC treated with chemoimmunotherapy combinations
AU - Cortellini, Alessio
AU - Ricciuti, Biagio
AU - Vaz, Victor R.
AU - Soldato, Davide
AU - Alessi, Joao V.
AU - Dall'olio, Filippo G.
AU - Banna, Giuseppe L.
AU - Muthuramalingam, Sethupathi
AU - Chan, Samuel
AU - Majem, Margarita
AU - Piedra, Aida
AU - Lamberti, Giuseppe
AU - Andrini, Elisa
AU - Addeo, Alfredo
AU - Friedlaender, Alex
AU - Facchinetti, Francesco
AU - Gorriá, Teresa
AU - Mezquita, Laura
AU - Hoton, Delphine
AU - Valerie, Lacroix
AU - Nana, Frank Aboubakar
AU - Artingstall, James
AU - Comins, Charles
AU - Di Maio, Massimo
AU - Caglio, Andrea
AU - Cave, Judith
AU - McKenzie, Hayley
AU - Newsom-Davis, Thomas
AU - Evans, Joanne S.
AU - Tiseo, Marcello
AU - D'Alessio, Antonio
AU - Fulgenzi, Claudia A.M.
AU - Besse, Benjamin
AU - Awad, Mark M.
AU - Pinato, David J.
N1 - Publisher Copyright:
©
PY - 2022/2/16
Y1 - 2022/2/16
N2 - Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations. Methods In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria. Results Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were overweight; and 14.5% were obese. Overweight and obese patients were more likely aged ≥70 years (p=0.00085), never smokers (p<0.0001), with better baseline Eastern Cooperative Oncology Group - Performance Status (p=0.0127), and had lower prevalence of central nervous system (p=0.0002) and liver metastases (p=0.0395). Univariable analyses showed a significant difference in the median OS across underweight (15.5 months), normal weight (14.6 months), overweight (20.9 months), and obese (16.8 months) patients (log-rank: p=0.045, log rank test for trend: p=0.131), while no difference was found with respect to the median PFS (log-rank for trend: p=0.510). Neither OS nor PFS was significantly associated with baseline BMI on multivariable analysis. Conclusions In contrast to what was observed in the context of chemotherapy-free ICI-based regimens, baseline BMI does not affect clinical outcomes from chemoimmunotherapy combinations in patients with advanced NSCLC.
AB - Introduction It has been recognized that increasing body mass index (BMI) is associated with improved outcome from immune checkpoint inhibitors (ICIs) in patients with various malignancies including non-small cell lung cancer (NSCLC). However, it is unclear whether baseline BMI may influence outcomes from first-line chemoimmunotherapy combinations. Methods In this international multicenter study, we evaluated the association between baseline BMI, progression-free survival (PFS) and overall survival (OS) in a cohort of patients with stage IV NSCLC consecutively treated with first-line chemoimmunotherapy combinations. BMI was categorized according to WHO criteria. Results Among the 853 included patients, 5.3% were underweight; 46.4% were of normal weight; 33.8% were overweight; and 14.5% were obese. Overweight and obese patients were more likely aged ≥70 years (p=0.00085), never smokers (p<0.0001), with better baseline Eastern Cooperative Oncology Group - Performance Status (p=0.0127), and had lower prevalence of central nervous system (p=0.0002) and liver metastases (p=0.0395). Univariable analyses showed a significant difference in the median OS across underweight (15.5 months), normal weight (14.6 months), overweight (20.9 months), and obese (16.8 months) patients (log-rank: p=0.045, log rank test for trend: p=0.131), while no difference was found with respect to the median PFS (log-rank for trend: p=0.510). Neither OS nor PFS was significantly associated with baseline BMI on multivariable analysis. Conclusions In contrast to what was observed in the context of chemotherapy-free ICI-based regimens, baseline BMI does not affect clinical outcomes from chemoimmunotherapy combinations in patients with advanced NSCLC.
KW - immunity
KW - lung neoplasms
KW - metabolic networks and pathways
KW - programmed cell death 1 receptor
UR - http://www.scopus.com/inward/record.url?scp=85124775775&partnerID=8YFLogxK
U2 - 10.1136/jitc-2021-004374
DO - 10.1136/jitc-2021-004374
M3 - Article
C2 - 35173031
AN - SCOPUS:85124775775
SN - 2051-1426
VL - 10
JO - Journal for ImmunoTherapy of Cancer
JF - Journal for ImmunoTherapy of Cancer
IS - 2
M1 - e004374
ER -